1610796-02-5

Basic information

• Product Name: Azido-PEG12-NHS ester
• Synonyms: Azido-PEG12-NHS ester;N3-PEG12-CH2CH2COONHS Ester
• CAS NO: 1610796-02-5
• Molecular Formula: C31H57N4O16+
• Molecular Weight: 741.80148
• Mol File: 1610796-02-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Azido-PEG12-NHS ester(CAS DataBase Reference)
• NIST Chemistry Reference: Azido-PEG12-NHS ester(1610796-02-5)
• EPA Substance Registry System: Azido-PEG12-NHS ester(1610796-02-5)

Safety Data

• Hazardous Substances Data: 1610796-02-5(Hazardous Substances Data)

Usage

Uses

Used in Bioconjugation:
Azido-PEG12-NHS ester is used as a bioconjugation agent for the covalent attachment of biomolecules, such as proteins, peptides, or other molecules, to various surfaces or other biomolecules. The NHS ester group reacts with primary amines, forming stable amide bonds, while the dPEG12 spacer provides a hydrophilic and non-immunogenic environment that reduces aggregation and non-specific interactions.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Azido-PEG12-NHS ester is used as a component in the development of drug delivery systems. The hydrophilic dPEG12 spacer improves the solubility and bioavailability of drugs, while the NHS ester group allows for the attachment of drug molecules to the delivery system, enhancing their stability and controlled release.
Used in Diagnostics:
Azido-PEG12-NHS ester is also utilized in the development of diagnostic tools, such as imaging agents or biosensors. The azide function can be used for the selective labeling of target molecules, while the dPEG12 spacer provides a hydrophilic environment that reduces background signals and improves the sensitivity of the diagnostic tool.
Used in Material Science:
In the field of material science, Azido-PEG12-NHS ester is used as a building block for the creation of hydrogels, micelles, or other nanostructures with specific properties. The dPEG12 spacer contributes to the hydrophilicity and non-immunogenicity of the resulting materials, while the reactive NHS ester group allows for the incorporation of various functional groups or molecules.

Upstream product

• 112-27-6 2,2'-[1,2-ethanediylbis(oxy)]bisethanol 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 1056024-94-2 3-{2-[2-(2-azidoethoxy)-ethoxy]ethoxy}propanoic acid 
• 252881-73-5 tert-Butyl 3-(2-(2-(2-azidoethoxyl)ethoxy)ethoxy)propanoate 
• 217817-01-1 tert-butyl 3-[2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]ethoxy]propanoate 
• 186020-66-6 3-{2-[2-(2-hydroxy-ethoxy)-ethoxy]-ethoxy}-propionic acid tert-butyl ester 
• 756525-95-8 2-methyl-2-propanyl 3-[2-(2-aminoethoxy)ethoxy]propanoate 
• 1629676-61-4 3-(2-(2-(2-(dibenzylamino)ethoxy)ethoxy))tert-butyl propionate 
• 850090-13-0 9-(p-toluenesulfonyloxy)-3,6-diocanonanoic acid tert-butyl ester 
• 1271728-79-0 tert-butyl 3-(2-(2-azidoethoxy)ethoxy)propanoate 
• 1312309-63-9 3-(2-(2-azidoethoxy)ethoxy)propanoic acid 
• 1312309-62-8 tert-butyl 3-(2-(2-((methylsulfonyl)oxy)ethoxy)ethoxy)propanoate 
• 133803-81-3 2-methyl-2-propanyl 3-[2-(2-hydroxyethoxy)ethoxy]propanoate 

Downstream Products

• 1340586-75-5 azido-PEG4-alkane-3',5'-cytidine-bisphosphate 

Relevant articles and documents

NOVEL CONNECTED BODY AND USE THEREOF IN SPECIFIC CONJUGATION BETWEEN BIOMOLECULE AND DRUG

PROBLEM TO BE SOLVED: To provide: a method for producing a connected body; a method for using the connected body in the production of a uniform conjugate; and a method for applying the conjugate in the treatment of cancer, infectious diseases, and autoimmune diseases. SOLUTION: A novel connected body is provided that includes a 2,3-di-substituted succinic acid group or a 2-mono-substituted or 2,3-di-substituted fumaric acid or maleic acid (trans (E)- or cis (Z)-butenedioic acid) group for conjugating 2 or more compounds/cytotoxic agents per connected body with a cell-binding molecule by specifically bridge-linking to a pair of thiol on the cell-binding molecule. The connected body is exemplified by the following general formula. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

CROSS-LINKED PYRROLOBENZODIAZEPINE DIMER (PBD) DERIVATIVE AND ITS CONJUGATES

A novel cross-linked cytotoxic agents, pyrrolobenzo-diazepine dimer (PBD) derivatives, and their conjugates to a cell-binding molecule, a method for preparation of the conjugates and the therapeutic use of the conjugates.

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE

What provided is the conjugation of cytotoxic to a cell-binding molecule with a bis-linker(dual-linker) as shown in Formula (I). It provides bis-linkage methods of making a conjugate of a cytotoxic drug molecule to a cell-binding agent in a specific manner. It also relates to application of the conjugates for the treatment of a cancer, or an autoimmune disease, or an infectious disease.

CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS

The present invention relates to linkers having a group of propiolyl, substituted acryl (acryloyl), or disubstituted propanoyl, and using such linkers for the conjugation of compounds, in particular, cytotoxic agents to a cell-binding molecule.

SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF

The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)- butenedioic), or acetylenedicarboxyl group for conjugation of a cytotoxic agent, and/or one or more different functional molecules per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.

NOVEL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF DRUGS TO A BIOLOGICAL MOLECULE

The present invention relates to novel linkers containing a 2,3-disubstituted succinic group, or 2-monosubstituted, or 2,3-disubstituted fumaric or maleic (trans (E)- or cis (Z)- butenedioic) group for conjugation of two or more compounds/cytotoxic agents per linker to a cell-binding molecule, through bridge linking pairs of thiols on the cell-binding molecule specifically. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders.